Vyant Bio Investor Relations Material
Latest events
Q3 2022
Vyant Bio
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Vyant Bio Inc
Access all reports
Vyant Bio, Inc. operates as a biotechnology drug discovery company. The company discovers, develops, and commercializes antimicrobial drugs to treat acute respiratory tract infections, including pneumonia and influenza.
Latest articles
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Alphabet's Unstoppable Rise: From Stanford to Global Tech Leader
Discover Alphabet's rise from a university project to a global tech leader, highlighting its growth, diversification, and visionary leadership.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States